AdAlta

AU: 1AD

Market CapAU$20m

Last Close AU$0.08

AdAlta is an Australian healthcare company focused on using its proprietary i-body discovery platform to target diseases, with an initial focus on IPF. AdAlta has also licensed its platform to GE Healthcare for the purpose of diagnostic imaging.

More AdAlta content >

Investment summary

AdAlta is a clinical-stage company that uses its proprietary i-body discovery platform to target diseases, with an initial focus on conditions involving fibrosis. Its lead programme is AD-214, a C-X-C chemokine receptor type 4 (CXCR4) inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF). IPF is an orphan progressive lung disease that remains a significant unmet medical need, despite two approved blockbuster therapies. Beyond AD-214, AdAlta has licensed the i-body platform to GE Healthcare for diagnostic imaging, which recently advanced into preclinical testing. The company has also signed a collaboration with Carina Biotech to develop CAR-T therapies.

Y/E Jun
Revenue (A$m)
EBITDA (A$m)
PBT (A$m)
EPS (c)
P/E (x)
P/CF (x)
2020A 3.8 (5.8) (5.9) (3.62) N/A N/A
2021A 4.0 (5.4) (5.5) (2.35) N/A N/A
2022E 3.2 (7.5) (7.6) (3.03) N/A N/A
2023E 3.2 (7.6) (7.7) (3.06) N/A N/A
Industry outlook

It is estimated that over 100,000 people in the United States and a similar number in Europe have IPF. It is a progressive disease where median survival after diagnosis is three to five years and the two approved medications for the condition (US$2.9bn in sales in 2019) have limited efficacy and toxicity issues.

Last updated on 20/10/2021
Content on AdAlta
AdAlta – Moving into CAR-T
Healthcare | Update | 31 August 2021
Medicine doctor with stethoscope in hand and icon insurance for health. Medical network connection on virtual screen interface. Innovation and modern medical technology concept
AdAlta – Moving to an inhaled formulation
Healthcare | Update | 22 July 2021
Medicine doctor with stethoscope in hand and icon insurance for health. Medical network connection on virtual screen interface. Innovation and modern medical technology concept
AdAlta – Validation from GE Healthcare
Healthcare | Update | 26 May 2021
Medicine doctor with stethoscope in hand and icon insurance for health. Medical network connection on virtual screen interface. Innovation and modern medical technology concept
View more
Register to receive research on AdAlta as it is published
Share price graph
Balance sheet
Forecast net cash (A$m) 3.6
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual (17.0) (27.8) (33.6)
Relative* (19.0) (29.7) (45.0)
52-week high/low A$0.2/A$0.1
*% relative to local index
Key management
Paul MacLeman Chairman
Tim Oldham CEO